A Phase 2 Multi-center, Open-label, Single Arm Study of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

Inclusion Criteria: 1. Patients with functional or non-functional, well-differentiated, locally advanced unresectable or metastatic NETs of the GI tract, lung, or pancreas who have received 2 or less prior lines of therapy excluding somatostatin analogs 2. Patients with functional NETs may enroll if: 1. the patient has been on a stable dose of an somatostatin analogs for ≥12 weeks and 2. the patient has experienced disease progression while on stable somatostatin analogs dose 3. Patients must have 1 or more measurable target lesions by RECIST v1.1 4. Age: 18 years or older 5. Eastern C…